AIM ImmunoTech Resumes Trading on NYSE American

Rhea-AI Summary

AIM ImmunoTech Inc. (NYSE American: AIM) has announced the resumption of trading of its common stock on the NYSE American exchange effective June 17, 2025. The company's shares are trading under the ticker symbol 'AIM' with CUSIP number 00901B303. The resumption of trading on NYSE American, one of the major U.S. stock exchanges, marks an important milestone for the company's market presence.

Positive

• Resumption of trading on a major U.S. exchange (NYSE American) enhances company visibility and trading accessibility
• Maintaining NYSE American listing indicates compliance with exchange requirements

Negative

• Previous trading suspension suggests potential compliance or regulatory issues that led to the halt

Company trading under the ticker “AIM” NYSE American effective at the start of trading today, Tuesday, June 17th

OCALA, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that its common stock has resumed trading on the NYSE American under the symbol "AIM" and CUSIP 00901B303, effective at the start of trading today, June 17, 2025.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen^® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

FAQ

When did AIM ImmunoTech (AIM) resume trading on NYSE American?

AIM ImmunoTech resumed trading on NYSE American effective June 17, 2025, at the start of trading.

What is AIM ImmunoTech's new ticker symbol and CUSIP on NYSE American?

AIM ImmunoTech is trading under the ticker symbol 'AIM' with CUSIP number 00901B303.

Why was AIM ImmunoTech's stock previously suspended from trading?

The press release does not provide information about the reasons for the previous trading suspension.

What are the implications of AIM stock resuming trading on NYSE American?

Resuming trading on NYSE American indicates compliance with exchange requirements and provides enhanced visibility and accessibility for investors.